NASDAQ:BTD

Bitcoin drop knocks out $500 million in bullish crypto bets as inflation fears weigh on markets

Business News·Finance·NASDAQ:BTD·News·Stock Market

Bitcoin Depot Faces Nasdaq Suspension as Crypto ATM Sector Struggles

Micware shares jumped 97.7% to $9.33 in premarket U.S. trading Wednesday, rebounding above last week’s $8 IPO price after closing Tuesday at $4.72. Toyota disclosed beneficial ownership of 6.86 million Micware shares, or 11.6%. The Japanese automotive software company raised $22.8 million in its Nasdaq debut.

May 20, 2026

Genomic Test Could Spare Millions of Breast Cancer Patients Chemotherapy, Landmark Study Finds
May 29, 2026, 8:16 PM EDT. A landmark study reveals that millions of breast cancer patients could safely skip chemotherapy thanks to the Prosigna genomic test, which analyses tumor genes to assess recurrence risk. The international OPTIMA trial, involving 4,429 patients, showed a 93.7% five-year cancer-free survival rate for those who avoided chemotherapy, nearly matching the 94.9% rate for those treated with it. Karen Bonham, a trial participant, described her relief upon learning she would not need chemotherapy, attributing her cancer-free status nine years post-diagnosis to the test's guidance. Experts hail the findings as gamechanging, potentially transforming breast cancer treatment by reducing unnecessary chemotherapy and its side effects, while maintaining patient safety.